Product hub

Product hub: CD34+ haematopoietic stem cells: One cell type, multiple viable sources

Posted: 27 September 2022 | | No comments yet

Learn how you can mobilise CD34+ haematopoietic stem cells and how they can be isolated immediately after collection.

With the recent US Food and Drug Administration (FDA) approval of bluebird bio’s Zynteglo, the first autologous CD34+ based gene therapy for beta thalassemia, haematopoietic stem cells (HSCs) are quickly taking centre stage for advanced therapeutics. BioIVT has more than 35 years’ experience as a biospecimen provider and can deliver the full potential of these cells, from optimal source material such as mobilised leukopaks, bone marrow aspirate and cord blood.

READ IN FULL

Related organisations

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.